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Abstract
Recent clinical evidence supports a link between 25-hydroxyvitamin D insufficiency (serum 25-hydroxyvitamin D [25(OH)D]
levels ,30 ng/mL) and Parkinson’s disease. To investigate the effect of 25(OH)D depletion on neuronal susceptibility to
toxic insult, we induced a state of 25(OH)D deficiency in mice and then challenged them with the dopaminergic neurotoxin
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We found there was no significant difference between control and
25(OH)D-deficient animals in striatal dopamine levels or dopamine transporter and tyrosine hydroxylase expression after
lesioning with MPTP. Additionally, we found no difference in tyrosine hydroxylase expression in the substantia nigra pars
compacta. Our data suggest that reducing 25(OH)D serum levels in mice has no effect on the vulnerability of nigral
dopaminergic neurons in vivo in this model system of parkinsonism.
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Introduction
Multiple factors, including increased oxidative stresses, varying
genetic susceptibility, mitochondrial dysfunction, proteasomal
dysfunction, inflammation and premature apoptosis contribute to
the pathophysiology of Parkinson’s disease (PD) [1]. Furthermore,
such environmental factors as vitamin D status may modify PD
risk and/or progression [2]. Deficient and insufficient vitamin D
status has been associated with PD in one case report and several
epidemiologic studies [3,4]. Whether 25(OH)D deficiency states
are causal or merely correlative in PD remains poorly understood.
Despite this knowledge limitation, many clinicians recommend
vitamin D supplementation to patients as a means to prevent or
delay progression of PD. Therefore, it is important to clarify the
role, if any, that hypovitaminosis plays in PD-related pathology.
The goal of this study is to address this gap in our knowledge.
The term ‘‘vitamin D’’ frequently refers to the family of
compounds that include the nutritional supplements (cholecalcif-
erol (vitamin D3) and ergocalciferol (vitamin D2)), 25-hydro-
xyvitamin D (25(OH)D), and the biologically active vitamin D
hormone, 1,25-dihydroxyvitamin D (1,25OH2D)). Both vitamin
D2 and vitamin D3 are rapidly hydroxylated to 25(OH)D, the
body’s primary storage form for ‘‘vitamin D’’ and the best
indicator of vitamin D status. This 25(OHD) metabolite has much
higher circulating concentrations in serum and has a much longer
half-life than the serum 1,25OH2D, which is considered the
hormonal form of vitamin D. The hormonal form of vitamin D,
1,25OH2D is dependent on the substrate 25-hydroxyvitamin D.
Therefore, circulating 1,25OH2D concentrations generally corre-
late with 25(OH)D concentrations. However, concentrations of the
biologically active vitamin D hormone (1,25OH2D) are tightly
regulated and in our neurology clinical settings it is rare to find
patients who have normal renal function and abnormally low
1,25OH2D concentrations, even when 25(OH)D concentrations
suggest severe vitamin D deficiency.
Several lines of clinical evidence suggest the vitamin D hormone
may play a mechanistic role in the pathogenesis of PD. First,
genetic factors, such as finding the vitamin D hormone receptor b
allele BsmI polymorphism is more frequent in patients with PD
than healthy controls and 59 end SNPs on the VDR gene may
modulate risk and/or survival in patients with PD [3,4]. Second,
higher 25(OH)D serum levels are associated with reduced risk of
developing PD [5]. Third, we and others report that patients with
PD are more likely to have 25(OH)D insufficiency (defined as a
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controls or patients with Alzheimer’s disease [6,7]. Also, 25(OH)D
insufficiency is present early in the disease state (before patients are
clinically disabled) [8]. Fourth, in some, but not all cohorts,
25(OH)D levels are lower in patients with more advanced disease,
suggesting that as patients’ mobility declines so do 25(OH)D levels
or vice versa [6,9]. These observations have led to speculation that
low concentrations of 25(OH)D are involved in PD pathogenesis
and/or progression [10].
Laboratory evidence also suggests plausibility that the vitamin D
physiology may play a role in the PD. The hormone (1,25OH2D)
has been shown in multiple injury models relevant to stroke,
multiple sclerosis, and Alzheimer’s disease to differentially protect
both neuronal populations and glia via upregulation of L-type
calcium channels, immune modulation, increased antioxidant
function, improved neurotrophin expression
[11,12,13,14,15,16,17]. Similarly, 1,25OH2D appears to support
homeostasis of the dopaminergic neuronal populations affected in
PD. Both vitamin D hormone receptors and 1-alpha hydroxylase
enzyme (the activating enzyme for vitamin D hormone) are
expressed throughout the human brain, but are particularly
enriched in the large (likely dopaminergic) neurons of the
substantia nigra [18]. These findings have led to speculation that
vitamin D deficiency may leave nigrostriatal neurons more
vulnerable to insult [10,19]. Indeed, animal and cell culture
studies demonstrate that pre-treatment with vitamin D hormone
(1,25OH2D) protects dopaminergic neurons from 6-hydroxydo-
pamine and N-methyl-4-phenylpyridinium (MPP+) toxicity
[16,17]. Up to a point, increasing vitamin D hormone appears to
be neuroprotective. Alternatively, as Newmark and Newmark
suggest and as seen in traumatic brain injury models, functional
vitamin D deficiency (from reduced 25(OH)D, 1,25OH2Do r
vitamin D receptor dysfunction) may leave nigrostriatal neurons
more vulnerable to insult [10,19,20]. However, the effect of
reducing 25(OH)D concentrations (as seen in patients with PD) or
vitamin D hormone levels on the vulnerability of the nigrostriatal
system to insult has not been tested in vivo. To explore this
possibility, we determined if 25(OH)D deficiency in mice renders
the nigrostriatal system of those mice more vulnerable to insult by
the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP).
Materials and Methods
Ethics Statement, Animals and Behavioral Testing
All animal procedures were conducted in accordance with the
National Institutes of Health Guide for Care and Use of Laboratory
Animals and were approved by Emory University Institutional
Animal Care and Use Committee for these specific experiments.
Retired breeder (8–10 months of age) male C57Bl/6J mice were
purchased from Jackson Laboratory. Vesicular monoamine
transporter 2 hypomorph (VMAT2 LO) and wild type mice have
been previously described [21,22]. Mice were individually housed
on a 12 hour light: 12 hour dark cycle with ultraviolet-free bulbs
and were given food and water ad libitum. C57Bl/6J mice were
randomly assigned to either the control or depleted group.
Depleted mice were fed rodent chow devoid of vitamin D (Harlan
Teklad Catalog #TD.89123) while control mice were fed a chow
containing identical components plus vitamin D (Harlan Teklad
Catalog #TD.89124). These diets contain 0.47% calcium, 0.3%
phosphorus, 16.4% protein, 59.2% carbohydrate, and 10% fat by
weight with 3.9 Kcal/g. Therefore, under these conditions, diet (in
the control animals) was the only source of vitamin D; depleted
animals received no dietary vitamin D and could not make vitamin
D from UVB radiation. There was no difference between starting
body mass in the control and vitamin D depletion animal groups
prior to changing their chow (mean body mass 6 SEM- control
chow group- 30.4460.741 grams; depletion chow group-
30.6060.754 grams). Both groups of mice gained body mass on
the new chow formulation and no differences were observed
between control-fed and vitamin D depletion chow-fed groups at
the time of depletion (mean body mass 6 SEM- control chow
group- 34.7261.1 grams; depletion chow group- 33.3761.1
grams).
Vitamin D Determination
C57Bl/6J mice were subjected to the control or vitamin D-
deficient diet for 6 weeks prior to MPTP challenge. Before MPTP
challenge, blood was collected into a BD MicrotainerH Serum
Separation Tube from the lateral tail vein without restraint. Blood
was held on ice for 10 minutes and then centrifuged at 10,000 x g.
Serum 25(OH)D levels were assayed by 25(OH)D Direct EIA kit
(Immunodiagnostic Systems, Fountain Hills, AZ) per manufactur-
er’s protocol to confirm depletion. Additionally, tail vein blood was
collected from VMAT2 LO and wild type (WT) mice for
25(OH)D measures.
MPTP Exposure
A diagram of the study design is shown (Figure 1). For the
MPTP lesioning phase, mice received daily subcutaneous injec-
tions at the nape of the neck of either phosphate-buffered saline
(PBS) or 15 mg/kg of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyr-
idine (as a MPTP-HCl salt Sigma-Aldrich, St. Louis, MO) in PBS
for 4 days. Mice were allowed to recover for 7 days after the last
MPTP dose and then sacrificed by either live decapitation for
tissue collections or by isofluorane anesthetizing and transcardially
perfusion with 4% paraformaldehyde in PBS (PFA).
Motor Behavioral Assessment by Forepaw Stride Length
Forepaw stride length was measured as described previously
[23,24] pre- and post-vitamin D depletion. Individually housed
mice were allowed to acclimate to their home cage for a minimum
of three days prior to assays. Each mouse was transferred briefly to
a novel cage. The home cage was turned on its side at the end of a
2 inch wide by 14 inch long track with white paper lining the
bottom. The mice were briefly suspended by the tail over a tray of
nontoxic, black ink so the mice could ink their forepaws, were then
placed at the beginning of the track opposite their home cage and
were allowed to walk to their home cage. Stride length was only
measured as a minimum of 4 uninterrupted strides. If the mouse
paused during the procedure, the mouse was not allowed to reach
its home cage and was put back in the novel cage to repeat the
procedure. If a mouse failed to complete the task again, it was
excluded from the behavioral assessment. There was no difference
between groups for ability to complete the task. Stride lengths were
scored as the distance between successive forepaw pad imprints.
The average of at least 4 strides was taken for each mouse.
After 25(OH)D depletion was confirmed, mice were trained
daily on the task for 5 days. On the 6
th day, forepaw stride lengths
were collected for pretreatment baseline measures. Mice then
received daily subcutaneous injections of either phosphate
buffered saline (PBS) or 15 mg/kg of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP-HCl salt used from Sigma) in PBS for
4 days. Mice were allowed to recover for 7 days. On the 6
th day of
recovery, mice received an additional day of reinforcement
training on the forepaw stride length task. On the 7
th day,
forepaw stride length measures were taken.
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Tissues were analyzed by western blotting technique as
previously [21,25]. Unilateral striatum was homogenized with a
tissue tearer (Biospec Products, Inc., Bartlesville, OK) in a
homogenization buffer of 0.32 M sucrose, 5 mM HEPES
pH 7.4 with 16 protease inhibitor cocktail (Sigma Aldrich).
Homogenates were centrifuged at 12006g for 5 minutes at 4uC.
The post-nuclear lysate was collected and centrifuged at 20,0006g
for 45 minutes at 4uC. The resulting synaptosomal pellet was
resuspended in 100 ml of homogenization buffer. Protein concen-
trations were determined by BCA protein assay (Thermo
Scientific). 20 mg of protein lysate was electrophoresed on a
NuPAGE 10% Bis-Tris Gel (Invitrogen) and then transferred to a
0.2 mm PVDF membrane (Invitrogen). Blots were blocked in 8%
instant milk powder solution (Carnation) for 1 hour at 18–22uC.
Primary antibodies (rabbit polyclonal anti-TH and rat polyclonal
anti-DAT, Chemicon, Temecula, CA and mouse anti-tubulin,
Sigma-Aldrich, St. Louis, MO) were incubated with blots at 4uC
for 12–18 hours. Upon several washes, a HRP-conjugated
secondary antibody (Sigma) was incubated with the blots for 1
hour at 18–22uC. Blots were washed and then developed with the
Super Signal Dura substrate system (Thermo Scientific). Blots
were then imaged immediately using a Fluorchem Imaging system
(Alpha Innotech). Densitometric analyses were performed using
the accompanying software.
HPLC Analyses of MPP
+, Dopamine, and Metabolite
Levels
An Agilent 1100 Series Capillary HPLC system coupled with an
ESA Coulochem III electrochemical detector was used for
separation and quantification of dopamine, 3,4-dihydroxypheny-
lacetic acid (DOPAC) and homovanillic acid (HVA). Briefly, the
striatal region of each mouse was weighed and homogenized using
a sucrose media (0.32 M sucrose, 10 mM Tris base, 0.5 mM
EDTA) at 10% w/v. A 100 mL aliquot was taken and proteins
were precipitated by addition of 5 mL perchloric acid. Samples
were then spun at 10,000 x g for 3 minutes to pellet precipitated
proteins. 10 mL of each sample solution was injected and separated
using a Thermo Scientific C18 Aquasil column (2.1 x 150 mm,
100 A ˚). Mobile phase consisted of 50 mM citric acid, 1.8 mM
sodium heptane sulfonate, 0.2% trifluoroacetic acid (v/v),pH 3.0
(A) and acetonitrile (B). Gradient conditions were as follows: 3% B
at 0 min, 3% B at 8 min, 18% B at 19 min, 3% B at 20 min and
3% B at 35 min using a flow rate of 250 mL/min. Dopamine,
DOPAC and HVA were detected using electrodes set at potentials
of 2150 and +300 mV. Calibration curves were generated using
standards to convert peak area to concentration units.
MPP+ levels were measured similarly as described previously
[26,27]. Upon depletion mice were given a single dose of MPTP
(20 mg/kg, s.c.) and sacrificed 90 minutes later for striatal
dissection as described above. Bilateral striata were used for
detection. MPP+ iodide, acetonitrile ($99.9% HPLC grade),
sodium trichloroacetate (TCA, 97.0%) and potassium phosphate
monobasic (($99.0%) were purchased from Sigma Aldrich (St.
Louis, MO). For analysis of MPP
+ levels, striata were sonicated
(Branson S-250A with a double stepped microtip; Danbury, CT)
in 5 volumes of 5% TCA and centrifuged for 10 min at 14,000 g.
MPP
+ levels were determined by analysis of supernatant using an
Agilent Model 1200 HPLC equipped diode array detector
operated at a wavelength of 290 nm. Separation was achieved
on a reverse phase Altima C18 column (5 um, L=150 mm,
ID=4.6 mm, Catalog No. 88052; Alltech Associates Inc., Deer-
field, IL) with a mobile phase consisting of 89% 50 mM KH2PO4
and 11% acetonitrile. MPP
+ was identified by comparison of
retention time with known standards and concentrations were
calculated from a 6-point standard curve of known concentrations
of MPP
+. Protein concentrations were determined by Bradford
Assay.
Immunohistochemistry of Striatal and Nigral
Dopaminergic Markers
Perfused brains were kept at 4uC for 12 hours in 4% PFA.
Brains were then transferred to 30% sucrose and stored at 4uC.
Forty mm sections were prepared (Microm HM450) and trans-
ferred to Tris-buffered saline and stored at 4uC until use. For
immunohistochemical staiining, thin sections were washed six
times in 16TBS to remove all traces of PFA. Thin sections were
incubated with a rat monoclonal anti-dopamine transporter (DAT)
(1:750; Chemicon), or a rabbit polyclonal anti-tyrosine hydroxy-
lase (TH) antibody (1:2000; Chemicon) overnight at 4uC and then
incubated in a biotinylated-goat anti-rat or goat anti-rabbit
secondary antibody (Jackson Immunoresearch, West Grove, PA)
for 1 hour at room temperature. Visualization was performed
using 0.03% 3,39-diaminobenzidine (Sigma Aldrich, St Louis,
MO) at room temperature.
Statistical Analyses
All statistical analyses were performed using Graph Pad Prism
5.0. Student t-tests were performed for initial two group
comparisons with significant values reported as p,0.05. Two-
way AVOVA analyses were performed on all multi-group
comparisons with Bonferroni post-hoc tests to determine
significant interactions. Significant values are reported as
p,0.05.
Figure 1. Schematic of experimental design to deplete mice of 25(OH)D levels and challenge with MPTP. On day 1, mice were weighed
and randomly assigned to either a group receiving vitamin D depleted chow or a group receiving control chow supplemented with vitamin D. Mice
were weighed weekly to check for changes in body mass. After 36 days, 25(OH)D depletion was confirmed by ELISA assay. Then, mice were trained
daily to learn the forepaw stride length task from days 44–48. On day 49, baseline behavior was measured. On day 50, MPTP injections began. Mice
received a daily injection of either PBS or 15 mg/kg MPTP for 4 days. The mice were allowed to recover for 7 days. On day 60, post-MPTP behavior
was measured prior to sacrificing the mice.
doi:10.1371/journal.pone.0039227.g001
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Short Term 25(OH)D Depletion had no Effect the Overall
Health or Behavior of the Mice
In order to test the effect of 25(OH)D deficiency on the
vulnerability of nigrostriatal neurons, we first depleted mice of
serum levels of 25(OH)D. Since a laboratory animal’s sole source
of vitamin D is dietary, mice were transferred from standard
rodent chow (Purina) to a vitamin D deficient diet to specifically
deplete serum 25(OH)D levels. Serum 25(OH) D levels are widely
regarded as the most reliable predictor of vitamin D status due to a
longer serum half-life (,15 days) versus 1,25(OH)2D with a much
shorter serum half-life (,15 hours) [28]. Therefore, we used serum
25(OH)D levels to define vitamin D status as it is done in most
animal and human studies. After 6 weeks on depleted chow, serum
25(OH)D levels were depleted by nearly 80% (Figure 2A). Vitamin
D control chow-fed and depletion chow-fed mice had a mean 6
SEM 25(OH)D serum level of 43.960.7 ng/ml and 7.1760.4 ng/
ml, respectively (n=6; p,0.0001).
Next, we confirmed that 25(OH)D deficiency had no effect on
the mice’s ability to learn or perform a behavioral index of
nigrostriatal damage. Previously, gestational 25(OH)D deficiency
has been shown to affect dopamine-dependent locomotor behav-
iors in mice [29,30]. However, it is unknown whether 25(OH)D
deficiency during adulthood affects motor behaviors. We found
that 25(OH)D depletion had no effect on mean forepaw stride
length (Control Group- 6.2860.16 cm; Vitamin D Depletion
Group- 6.1460.22 cm) (Figure 2B). Thus, no overt effect on the
mice’s health or behavior during the 6 weeks of 25(OH)D
depletion was observed.
25(OH)D Depletion did not Further Exacerbate the Effects
of MPTP in Mice
We hypothesized that 25(OH)D depletion would not affect the
dopamine system alone, rather render the system more vulnerable
to future insult. To test this, we challenged 25(OH)D-depleted
mice with the dopaminergic neurotoxin MPTP (4 x 15 mg/kg) to
produce a mild lesion resulting in approximately 50–60%
reduction of striatal dopamine. This dose was chosen so that
exacerbation or protection could be detected in the vitamin D-
depleted animals. MPTP lesion was confirmed by measuring
changes in dopamine and markers of dopamine neuron. Striatal
dopamine (Figure 3A) was significantly reduced by 60% in MPTP-
lesioned animals as compared to saline-treated animals (Control/
Saline- 25.54663.6 pmol/mg of protein, Control/MPTP-
10.52361.2 pmol/mg of protein; n=4). Next, we investigated
the effect of 25(OH)D status on the magnitude of dopamine injury.
25(OH)D depletion had no effect on striatal dopamine levels after
MPTP lesion. A similar 60% reduction in dopamine levels after
MPTP treatment in 25(OH)D depleted animals was observed
(Vitamin D Depletion/Saline- 32.73561.4 pmol/mg of protein,
Vitamin D Depletion/MPTP- 13.36965.0 pmol/mg of protein;
n=4). While 25(OH)D depleted animals trended towards having
higher dopamine, there was no significant difference in striatal
dopamine levels observed between vitamin D control chow-fed
and depleted chow fed animals with or without MPTP lesion.
In order to determine whether 25(OH)D deficiency exacerbates
MPTP-inducedbehavioralchanges,forepawstridelengthmeasures
were performed. MPTP treatment did not significantly affect
forepaw stride length measured at the end of the study (Control/
Saline Group- 6.4660.26 cm; Control/MPTP Group-
6.4760.26 cm; Vitamin D Depletion Saline Group-
7.0260.29 cm; Vitamin D Depletion MPTP Group-
5.9760.25 cm; n=729) (Figure 3B). Interestingly, 25(OH)D
deficient-MPTP lesioned mice had significantly shorter forepaw
stride lengths than mice that were 25(OH)D deficient-saline treated
(*, p,0.05).
Sincechangesinmarkersofdopamineneuronintegritycanbeseen
intheabsence ofanybehavioraldeficit andareoften changedwhen
dopamine levels are altered, we next investigated the effect of
25(OH)Ddepletionofexpressionofmarkersofdopamineneuronsin
the nigrostriatal system. A significant 46% and 49% reduction in
striatal tyrosine hydroxylase (the rate limiting step in dopamine
synthesis) and dopamine transporter protein levels were observed
with MPTP lesion, respectively (Figures 4); however, 25(OH)D
depletiondidnotexacerbatethetotallossofterminalmarkersinthis
paradigm. Additionally, immunohistochemical analyses revealed a
dramatic reduction in both of the striatal TH (Figure 5A) and DAT
levels(datanotshown)andthenigralTHlevels(Figure5B)ofMPTP
lesioned animals that were not further exacerbated by 25(OH)D
depletion. Thus, 25(OH)D deficiency has no effect on expression of
markers of dopamine neuron health inmice.
It is possible that 25(OH)D deficiency could affect the
metabolism of the MPTP neurotoxin obscuring any effect that
25(OH)D depletion has on the vulnerability of the nigrostriatal
system. Therefore, we tested the ability of 25(OH)D deficiency to
interfere with MPTP metabolism. In a separate cohort of mice, we
Figure 2. Short term 25(OH)D depletion has no observable
effect on mouse locomotor behavior. A) Serum 25(OH)D levels
after 6 weeks on either control or vitamin D depletion rodent chow.
Results are presented as absolute mean values (ng/ml) 6 SEM for eight
animals per group (***p,0.0001.) B) Pre-MPTP lesion stride length
measures.
doi:10.1371/journal.pone.0039227.g002
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single dose of MPTP after 25(OH)D depletion (Figure 6).
Therefore, MPTP metabolism as measured by MPP+ levels is
not altered by 25(OH)D depletion.
25(OH)D Levels are not different in Mice with Acute or
Chronic Dopamine Deficiency
Because 25(OH)D levels are reportedly lower in patients with
more advanced PD, we hypothesized that perhaps acute or
chronic dopamine loss drives the lower levels of serum 25(OH)D
observed in patients with PD. To test this possibility, we also
determined whether dopaminergic neuron damage acutely affect-
ed 25(OH)D serum levels. In mice on the vitamin D complete
chow, there were no differences in 25(OH)D serum levels between
mice treated with MPTP and those treated with saline after ten
days of lesion (Control/Saline Group- 40.4061.1 ng/ml; Con-
trol/MPTP Group- 40.6061.1 ng/ml; Vitamin D Depletion/
Saline Group- 6.6060.7 ng/ml; Vitamin D Depletion/MPTP
Group- 5.9161.4 ng/ml; n=4; ***, p,0.0001)(Figure 7). How-
ever, the half-life of 25(OH)D serum levels are sufficiently long
that 25(OH)D concentration changes could have been obscured
over the course of only 10 days.
Therefore to test the effect of chronic dopamine deficiency as
seen in PD on 25(OH)D serum levels, we used a mouse model that
more closely matches the chronic state of dopamine deficiency, the
vesicular monoamine transporter 2 hypomorph (VMAT2 LO)
mouse model. These mice have severe impairment of their ability
to package dopamine into synaptic vesicles for later release
resulting in enhanced turnover of dopamine with a chronic state
of hypodopminerigia similar to that seen in patients with PD
[21,22]. We measured serum 25(OH)D levels in both young mice
and old mice maintained on standard vitamin D complete rodent
chow to detect any changes in 25(OH)D status in these mice.
Interestingly, lifelong deficiency in dopamine levels has no effect on
25(OH)D levels (Figure 8). There were no differences in serum
25(OH)D levels in VMAT2 WT and LO mice in young (,3
months) or old (.12 months) mice. Also, older mice had
significantly higher serum 25(OH)D levels than younger mice
(***, p,0.0001). Therefore, in this model chronic dopamine
deficiency does not promote 25(OH)D deficiency when fed a
standard rodent chow diet.
Figure 3. Behavioral and neurochemical effects of 25(OH)D
depletion on MPTP susceptibility in mice. A) HPLC analysis of
striatal dopamine levels in mice lesioned with MPTP after 25(OH)D
depletion. Results are presented as raw values (pmol/mg protein 6
SEM; n=4, ***p,0.001). B) Post-lesion stride length was measured.
There are no significant difference control and vitamin D depletion
group animals with or without MPTP lesion. The difference within the
vitamin D depletion groups is significant (*, p,0.05) with an increase in
forepaw stride length in vitamin D depletion group not treated with
MPTP over control animals.
doi:10.1371/journal.pone.0039227.g003
Figure 4. Effects of 25(OH)D depletion on TH and DAT
expression in MPTP-lesioned mice. A) Western analyses of striatal
TH and DAT levels after MPTP lesion in vitamin D depletion mice. A
representative blot is shown. b-tubulin is shown as a loading control.
B,C) Densitometric analyses of striatal TH and DAT are shown (Relative
values 6 SEM; n=4, ***p,0.001), respectively.
doi:10.1371/journal.pone.0039227.g004
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With exception of bone and tooth health, the role that vitamin
D supplements, 25OHD and vitamin D hormone play in the
pathogenesis of disease has been understudied and underappre-
ciated. Because epidemiological data have suggested a link
between low 25(OH)D status and PD, we sought to investigate
the effects of 25(OH)D depletion in the MPTP mouse model- of
Figure 5. 25(OH)D depletion does not exacerbate loss of tyrosine hydroxylase staining in the striatum and nigra after MPTP lesion.
A) Representative TH staining of the striatum. B) Representative TH staining of the nigra.
doi:10.1371/journal.pone.0039227.g005
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reduce serum 25(OH)D levels and lesion animals with MPTP,
there was no relationship between serum 25(OH)D levels and the
magnitude of MPTP injury as measured by striatal and nigral
dopamine neuronal markers, striatal dopamine, and gait analysis.
Also, we found no difference in the status of dopaminergic
nigrostriatal neurons as measured above with serum 25(OH)D
deficiency alone. This suggests that in animals, low serum
25(OH)D levels may not predict dopamine neuronal health. It is
unlikely that 25(OH)D deficiency in PD patients is a surrogate
marker for some other metabolic changes such as in calcium or
parathyroid hormone levels as these levels are rarely altered in our
clinical population with 25(OH)D insufficiency (data not shown). It
is also unlikely based on previous studies that calcium levels are
affected in our model system [31]. While similarly designed studies
largely reduce serum vitamin D hormone levels (,60% reduction),
it is possible that vitamin D hormone levels remained high enough
throughout our study in 25(OH)D depleted mice to prevent any
exacerbation of MPTP toxicity [32]. Additionally, while 25(OH)D
concentrations are low early in the course of the disease [8], and in
one epidemiologic study lower concentrations of 25OHD were
associated with increased risk of PD [5], the duration of 25(OH)D
insufficiency in patients with PD prior to diagnosis is unknown.
Therefore, to better model chronic 25(OH)D insufficiency (and
obtain chronically low-normal or even deficient vitamin D
hormone levels), future studies should include longer duration of
25(OH)D depletion in animals.
MPTP is a reliable toxicant used to selectively lesion dopamine
neurons and is the only toxicant model available for animal studies
that also undoubtedly causes a parkinsonian syndrome in humans
[33]. While the MPTP mouse is the most common animal model
of PD, it is limited by several factors including peripheral and
central metabolism of MPTP to MPP+, expression of DAT on the
surface of target cells, and the inability to reproduce the non-
motor and progressive symptoms of the disease. We did not detect
any effect of 25(OH)D depletion on MPTP metabolism or DAT
levels under our experimental conditions (Figures 4 and 6). The
MPTP dosing paradigm described in the present study is designed
to cause a moderate loss of dopamine and terminal markers, which
allows for detection of exacerbation or attenuation of toxicity.
Therefore, any effect of 25(OH)D alone on MPTP susceptibility
should be revealed, and we feel that we selected the appropriate
dosage of MPTP for this study. Additional experiments using a
milder 4 x 10 mg/kg MPTP dosing paradigm also revealed no
effects of 25(OH)D depletion on MPTP toxicity (data not shown).
Chronic Perhaps other models of Parkinson’s disease (such as a
transgenic A53T a-synuclein mouse may yield different results
[34]. However, chronic dopamine depletion as seen in VMAT2
LO mice did not affect serum 25(OH)D levels (Figure 8) [21],
suggesting that dopamine status does not influence vitamin D
status.
Previously, we have demonstrated that changes in environmen-
tal factors during brain development can predispose the nigrostri-
atal system to damage later in life [26,27]. Similarly, during early
development, 25(OH)D deficiency profoundly affects brain
volume, cell proliferation, and cortical thickness in rats [35].
Additionally, drug-induced hyperlocomotion, increased striatal
DAT, and decreased dopamine turnover are seen in rats
developmentally deficient in 25(OH)D [29,30]. This suggests that
early deficiency during developmental periods can cause perma-
nent changes to the dopaminergic pathways that may persist into
adulthood [36] and future generations [37]. While others have
observed changes in dopamine homeostasis in other models of
25(OH)D depletion [23], we observed a small non-statistically
significant trend towards increased striatal dopamine in 25(OH)D
depleted animals (Figure 3A). When challenged with MPTP, these
Figure 6. MPP+ levels are not altered by 25(OH)D depletion.
Mice were fed vitamin D depleted chow for 50 days and given a single
dose of MPTP (20 mg/kg). MPP+ levels were measured by HPLC.
doi:10.1371/journal.pone.0039227.g006
Figure 7. MPTP lesioning does not affect serum 25(OH)D levels.
After MPTP lesion, serum 25(OH)D levels were measured to determine if
MPTP lesion had any effect (Control/Saline Group- 40.4061.1 ng/ml;
Control/MPTP Group- 40.6061.1 ng/ml; Vitamin D Depletion/Saline
Group- 6.6060.7 ng/ml; Vitamin D Depletion/MPTP Group-
5.9161.4 ng/ml; n=4 (***, p,0.0001).
doi:10.1371/journal.pone.0039227.g007
Figure 8. Serum 25(OH)D levels are not changed in VMAT2 LO
mice. Serum 25(OH)D levels were measured in both young (2–3 month
old) and old (12–15 month) VMAT2 WT and LO mice to determine loss
of dopamine has any effect on 25(OH)D serum levels No differences
were observed between WT and LO mice; however, older mice have
higher serum 25-hydroxyvitamin D levels than young mice (***,
p,0.0001).
doi:10.1371/journal.pone.0039227.g008
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whereas control chow fed animals had no change (Figure 3B). It is
unclear whether the observed differences in dopamine levels and
forepaw stride length are a result of 25(OH)D status; however,
changes in dopamine homeostasis are strongly correlated to
changes in performance in several behavioral tasks, including gait
analyses by forepaw stride length [23].
In humans, midlife 25(OH)D insufficiency is associated with
higher PD risk while higher serum levels are associated with
reduced risk of PD [5]. Whether 25(OH)D insufficiency is causal
or correlative remains unknown, but it has been proposed that the
vitamin D hormone (1,25OH2D) plays a protective role in the
health of the neurons affected in PD and that lower serum levels of
vitamin D predispose these neurons to damage. Indeed, pretreat-
ment of rat mesencephalic cultures with 1,25OH2D (the biolog-
ically active form of vitamin D) confers resistance of dopaminergic
neurons to MPP
+ (the active form of the toxin) [17]. More
recently, it was shown that administration of 1,25OH2D partially
restored TH expression in the nigra of 6-hydroxydopamine
lesioned rats [38]. Altering concentrations of 25(OH)D and/or
1,25OH2D could be protective by several distinct mechanisms,
including stimulating the action of growth factors, acting as an
antioxidant, or increasing glutathione production [17,35,39,40].
Interestingly, we did not find the inverse, i.e., that short term
25(OH)D depletion (for eight weeks) made dopaminergic nigral
neurons more susceptible to insult by MPTP. Therefore, our data
do not support the hypothesis that 25(OH)D status influences
dopaminergic neuronal health.
Perhaps studies of other alteration of vitamin D status and
models of PD (such as the transgenic A53T a-synuclein mouse or
the VMAT2 LO mouse) [21,34] would yield different results. It is
possible that more sustained 25(OH)D deficiency would have led
to increased vulnerability to insult, and this paradigm does not
lead to changes in other factors associated with chronic deficiency
that may be necessary to affect neuronal vulnerability. Alterna-
tively, some interaction between vitamin D status and other
genetic factors may affect risk of PD. It is also possible that vitamin
D supplementation may protect neuronal populations against
insult, but reduced 25(OH)D levels have little or no effect on the
viability and vulnerability of dopamine neurons. Thus, additional
studies are warranted to explore the role of 25(OH)D deficiency on
the long term health of dopaminergic neurons.
Conclusions
Our data suggest that short term 25(OH)D depletion over the
course of a few weeks does not render dopamine neurons more
susceptible to the neurotoxin, MPTP as we initially hypothesized.
However, additional studies are warranted to explore whether
more long-standing deficiency of 25(OH)D or gestational deple-
tion have a role in the laboratory in vivo and in vitro models of
dopaminergic neuronal vulnerability to toxins. These large future
studies are necessary to establish the role, if any, that vitamin D
supplements, vitamin D status or the active 1,25OH2D (hormone)
play PD pathophysiology.
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